Induction of anticardiolipin antibody and/or lupus anticoagulant in rabbits by immunization with lipoteichoic acid,lipopolysaccharide and lipid A

Abstract

It still remains unclear how anti-phospholipid antibody develops in a specific patient group, however, it is possible that certain microorganism(s) may cause anti-cardiolipin antibody (aCL) development since aCL is frequently detected in patients with Treponema pallidum (TP) and/or other infectious diseases. Accordingly, we conducted an investigation to clarify whether or not anticardiolipin antibody (aCL) and/or lupus anticoagulant (LA) can be induced in rabbits by immunization with Gram-positive or -negative microorganism derivatives, such as lipoteichoic acid, lipopolysaccharide and lipid A. We detected the induction of SLE type-aCL (β₂GPI-dependent) and LA in some rabbits immunized with lipid A and lipoteichoic acid, thereby suggesting that some microorganisms may contribute to even the production of pathogenic (SLE-type) antiphospholipid antibody.

Keywords

anticardiolipin antibody lupus anticoagulant microorganism derivative

Get full access to this article

View all access options for this article.

References

Roubey Ras. Autoantibodies to phospholipid-binding plasma proteins: A new view of lupus anticoagulants and other antiphospholipid autoantibodies. Blood 1994; 84: 2854-2867.

Triplett DA Protean clinical presentation of antiphospholipid-protein antibodies (APA) . Thromb Haemostasis 1995; 74: 329-337.

Matsuura E. et al. Anticardiolipin antibodies recognize β2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface . J Exp Med 1994; 179: 457-462.

Matsuda J. et al. Distinguishing β2-glycoprotein I dependent (systemic lupus erthematosus type) and independent (syphilis type) anticardiolipin antibody with Tween 20. Br J Haematol 1993; 85: 799-802.

Matsuda J. et al. Prevalence of β2-glycoprotein I antibody in systemic lupus erythematosus patients with β2-glycoprotein I dependent antiphospholipid antibodies. Ann Rheum Dis 1995; 51: 73-75.

Al-Saeed A. et al. The development of antiphospholipid antibodies in haemophilia is linked to infection with hepatitis C. Br JHaematol 1994; 88: 845-848.

Facer CA , Agiostratidou G. High levels of anti-phospholipid antibodies in uncomplicated and severe plasmodium falciparum and in P. Vivax malaria. Clin Exp Immunol 1994; 95: 304-309.

Vaarala P. , Vaara M. , Palosuo T. Effective inhibition of cardiolipin-binding antibodies in Gram-negative infections by vacterial lipopolysaccharide. Scand J Immunol 1988; 28: 607-612.

Exner T. et al. Guidelines for testing and revised criteria for lupus anticoagulants. SSC subcommittee for the standardization of lupus anticoagulants. Thromb Haemostasis 1991; 65: 320-322.

10.

Gotoh M. , Matsuda J. Human immunodeficiency virus rather than hepatitis C virus infection is relevant to the development of an anticardiolipin antibody. Am J Hematol 1995; 50: 220-222.

11.

Cheng H-M. IgA antiphospholipid antibodies in normal human saliva cross-react with bacterial lipopolysaccharide. Int Arch Allergy Imm 1993 ; 101: 297-298.

12.

Alving CR Antibodies to liposomes, phospholipids and phosphate esters. Chem Phys Lipids 1986; 40: 303-314.

13.

Blank M. et al. Immunization with anticardiolipin cofactor (Beta-2-glycoprotein I) induces experimental antiphosholipid syndrome in naive mice. JAutoimmun 1994; 7: 441-455.

14.

Pierangeli SS , Harris EN Induction of phospholipid-binding antibodies in mice and rabbits by immunization with human β2-glycoprotein I or anticardiolipin antibodies alone. Clin Exp Immunol 1989; 78: 233-238.